Merck’s pembrolizumab has a high likelihood of approval for the treatment of natural killer cell lymphomas.
Pembrolizumab is under clinical development by and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer...